Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues

May 03 2017

• By Mandy Jackson

Arrows miss target

Related Content

Filgotinib Progress At Higher Dose Justifies Gilead's Gamble

May 25 2016

Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases

Mar 20 2017

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Jan 13 2017

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

Nov 02 2016

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

Nov 02 2016

US, EU Nods For Gilead's Vemlidy To Enter Saturated Hep B Market

Nov 11 2016

Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

Apr 14 2017

Related Companies

Gilead Sciences, Inc.

Novartis AG

Intercept Pharmaceuticals, Inc.

Galapagos NV

Eli Lilly and Company

Incyte Corporation

AbbVie Inc.

Merck & Co., Inc.

Additional Topics

Commercial Sales & Earnings Business Strategies Market Access Pricing Strategies BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window